International Isotopes Inc
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Ther… Read more
International Isotopes Inc (INIS) - Net Assets
Latest net assets as of September 2025: $4.10 Million USD
Based on the latest financial reports, International Isotopes Inc (INIS) has net assets worth $4.10 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.85 Million) and total liabilities ($13.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.10 Million |
| % of Total Assets | 22.95% |
| Annual Growth Rate | 0.8% |
| 5-Year Change | 50.56% |
| 10-Year Change | 21.33% |
| Growth Volatility | 76.67 |
International Isotopes Inc - Net Assets Trend (2000–2024)
This chart illustrates how International Isotopes Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for International Isotopes Inc (2000–2024)
The table below shows the annual net assets of International Isotopes Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.35 Million | +7.69% |
| 2023-12-31 | $4.04 Million | -7.04% |
| 2022-12-31 | $4.34 Million | +59.02% |
| 2021-12-31 | $2.73 Million | -5.42% |
| 2020-12-31 | $2.89 Million | +2674.46% |
| 2019-12-31 | $-112.15K | -172.76% |
| 2018-12-31 | $154.13K | -55.57% |
| 2017-12-31 | $346.93K | -80.24% |
| 2016-12-31 | $1.76 Million | -50.99% |
| 2015-12-31 | $3.58 Million | -9.87% |
| 2014-12-31 | $3.98 Million | -17.98% |
| 2013-12-31 | $4.85 Million | -20.08% |
| 2012-12-31 | $6.06 Million | -18.38% |
| 2011-12-31 | $7.43 Million | +53.58% |
| 2010-12-31 | $4.84 Million | +19.13% |
| 2009-12-31 | $4.06 Million | -36.11% |
| 2008-12-31 | $6.36 Million | +166.05% |
| 2007-12-31 | $2.39 Million | +73.87% |
| 2006-12-31 | $1.37 Million | -19.13% |
| 2005-12-31 | $1.70 Million | +208.35% |
| 2004-12-31 | $551.00K | -7.24% |
| 2003-12-31 | $594.00K | -28.61% |
| 2002-12-31 | $832.00K | +8.19% |
| 2001-12-31 | $769.00K | -78.56% |
| 2000-12-31 | $3.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to International Isotopes Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12732128500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $131.67 Million | 3028.94% |
| Total Equity | $4.35 Million | 100.00% |
International Isotopes Inc Competitors by Market Cap
The table below lists competitors of International Isotopes Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
01 Communique Laboratory Inc
OTCQB:OONEF
|
$15.69 Million |
|
FRANCHETTI S.P.A.
F:D0E
|
$15.69 Million |
|
Gurktaler AG ST
VI:GAGS
|
$15.70 Million |
|
Kanpai Co., Ltd
TWO:1269
|
$15.70 Million |
|
Digital Multimedia Technology Co.Ltd
KQ:134580
|
$15.69 Million |
|
LAMEDITECH Co., Ltd.
KQ:462510
|
$15.69 Million |
|
Logindo Samudramakmur Tbk
JK:LEAD
|
$15.68 Million |
|
Aimflex Bhd
KLSE:0209
|
$15.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in International Isotopes Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,036,625 to 4,347,008, a change of 310,383 (7.7%).
- Net income of 8,574 contributed positively to equity growth.
- New share issuances of 11,969 increased equity.
- Other factors increased equity by 289,840.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.57K | +0.2% |
| Share Issuances | $11.97K | +0.28% |
| Other Changes | $289.84K | +6.67% |
| Total Change | $- | 7.69% |
Book Value vs Market Value Analysis
This analysis compares International Isotopes Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.48x to 5.42x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.01 | $0.05 | x |
| 2014-12-31 | $0.01 | $0.05 | x |
| 2015-12-31 | $0.01 | $0.05 | x |
| 2016-12-31 | $0.00 | $0.05 | x |
| 2017-12-31 | $0.00 | $0.05 | x |
| 2018-12-31 | $0.00 | $0.05 | x |
| 2019-12-31 | $-0.01 | $0.05 | x |
| 2020-12-31 | $0.00 | $0.05 | x |
| 2021-12-31 | $0.01 | $0.05 | x |
| 2022-12-31 | $0.01 | $0.05 | x |
| 2023-12-31 | $0.01 | $0.05 | x |
| 2024-12-31 | $0.01 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently International Isotopes Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.06%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 3.95x
- Recent ROE (0.20%) is below the historical average (7.82%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 18.03% | 6.87% | 0.56x | 4.70x | $66.80K |
| 2013 | -51.53% | -35.94% | 0.57x | 2.51x | $-2.94 Million |
| 2014 | -39.61% | -20.50% | 0.69x | 2.81x | $-1.94 Million |
| 2015 | -51.71% | -25.75% | 0.63x | 3.20x | $-2.17 Million |
| 2016 | -110.15% | -28.68% | 0.58x | 6.67x | $-2.05 Million |
| 2017 | 0.00% | -50.63% | 0.62x | 0.00x | $-3.63 Million |
| 2018 | 0.00% | -8.15% | 0.80x | 0.00x | $-684.20K |
| 2019 | 0.00% | -17.01% | 0.59x | 0.00x | $-1.30 Million |
| 2020 | 384.04% | 23.52% | 0.55x | 29.81x | $2.15 Million |
| 2021 | -33.04% | -9.34% | 0.59x | 5.98x | $-1.18 Million |
| 2022 | 6.98% | 2.71% | 0.69x | 3.74x | $-131.02K |
| 2023 | -21.53% | -7.08% | 0.73x | 4.19x | $-1.27 Million |
| 2024 | 0.20% | 0.06% | 0.81x | 3.95x | $-426.13K |
Industry Comparison
This section compares International Isotopes Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| International Isotopes Inc (INIS) | $4.10 Million | 18.03% | 3.36x | $15.69 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |